Skip to main content

A DKA Patient Requiring High Insulin Despite Adequate Fluid Management and IV Insulin Therapy

A 58-year-old lady presented with complaints of vomiting with fever for 4 days and pain abdomen for 2 days prior to admission. Diabetic Ketoacidosis. Her past medical history was significant for hypothyroidism for 8 years, hypertension for 10 years, type diabetes mellitus for 17 years (she says her diabetes started after an abdominal tumor removal- details of which is not available) . 

On general examination, she was conscious, alert and oriented. Her blood pressure was 120/80 mmHg, Pulse was 120/min, temperature was 99.5 degree F. Respiratory system examination showed normal vasicular breath sounds. On cardiac examination, S1 and S2 was audible with no murmur. Abdomen was soft and nontender. CNS examination found no neurological deficits. Her Urine report was positive for ketone body (++). Patient was diagnosed to have diabeteic ketoacidosis. {Her discharge summary and advice on discharge documents are attached below]:




Despite adequate fluid management her glucose levels even on day 5 of treatment remained around 350-400 with Insulin requirements above 350 IU per day. She had no history of intake of steroids in the recent past (though she had taken NSAIDs for few days). Despite detailed evaluation we could not locate any source of infection. She was having constant pruritis and we treated her with antihistaminics and also administered anti scabies medications after taking a Dermatology referral (after Insulin requirements came down). She was obese as per South Asian stds (BMI around 28) with waist circumference of around 105 cm. At this point we introduced Pioglitazone 7.5 mg to the Rx regimen and by day 7 the Insulin requirements came down to abt 60 IU per day. The doubts and queries.


1. Is there any reported case of such high Insulin requirement in DKA patients on Day 5 of Rx despite adequate fluid management and IV Insulin therapy?
2. Did we encounter a case of severe glucotoxicity or severe transient insulin resistance?
3. As we are planning to do a Fasting and Stimulated C Peptide on follow up , do we need to do any further work up( limitations of the setting are there)?

While discussing about this patient, she came to our office for follow-up and her reports are attached below:


Comments

Popular posts from this blog

55 years Old male with Bipolar affected disorder moving from depression to Manic to depression phase

Disclaimer:- This is a HIPAA de-identified open-online-patient-record with initial information in patient's voice, posted here December 2017 after collecting informed patient consent (form downloadable Click Here) This is a case of a 55 years old, diabetic, hypertensive patient who was diagnosed with Bipolar affected disorder since 1995. In 1995 due to financial loss he was attacked by this condition. He was seen by Dr. D. K Agarwala and diagnosed as BPAD-Depression phase and treated with lithium, sodium valporate, propranolol, Zeptol cr, Nitrosum - S.  With the treatment he was reasonably well but every 6 months of interval he appeared to have some disturbance like didn't want to talk to anybody, forgot to smile etc. They went to the doctor and treated accordingly and was continuing the treatment.  In the year of 2013, August he was diagnosed with BPAD-severe depression phase but, he was not responding well to the medications and then they went to NIMHANS for

Consent Forms

Hindi BMJ Consent form   Bengali BMJ Consent form English BMJ Consent form   Telegu BMJ Consent Form Telegu BMJ Consent Form   UDHC Consent Form                

drugs to avoid or use in terms of their pregnancy category

The optimal AEDs therapy of women with epilepsy who are of childbearing age is unclear because of a lack of conclusive data on the comparative teratogenicity of different antiseizure drugs and no antiepileptic drug has proven safe in pregnancy in terms of teratogenesis. Data on the comparative efficacy of various antiseizure drugs for controlling seizures during pregnancy are also quite limited, and there are no randomized trials in this setting. Treatment must be individualized for all patients. Women with epilepsy are classified as high risk during pregnancy and as there are no clear data indicating that any drug is without risk in pregnancy therefore, the antiseizure drug regimen should be optimized six months prior to planned conception.  Choice of antiepileptic drugs in women of childbearing age and  pregnant women with epilepsy:  1. T he antiseizure drug that stops seizures in a given patient is the one that should be used with an exception of valproate. 2.